ENDRA Life Sciences (NDRA) Capital Expenditures (2018 - 2025)

ENDRA Life Sciences (NDRA) has reported Capital Expenditures for 8 consecutive years, with $17280.0 the latest figure, recorded in Q1 2025.

• On a quarterly basis, Capital Expenditures fell 36.0% year-over-year to $17280.0 in Q1 2025; TTM through Dec 2025 was $17280.0, a 8.0% increase from a year earlier, with the FY2025 full-year figure at $17280.0, up 8.0% from the prior year.
• Capital Expenditures was $17280.0 for Q1 2025 at ENDRA Life Sciences, up from -$11000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $89353.0 in Q1 2022 and troughed at -$11000.0 in Q2 2024.
• A 5-year average of $31474.1 and a median of $27000.0 in 2023 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures surged 101.34% in 2021 and slumped 82.15% in 2023, its largest moves.
• Over 5 years, Capital Expenditures stood at $45000.0 in 2021, then fell by 14.3% to $38563.0 in 2022, then tumbled by 82.15% to $6884.0 in 2023, then tumbled by 259.79% to -$11000.0 in 2024, then jumped by 257.09% to $17280.0 in 2025.
• The last three Capital Expenditures figures came in at $17280.0 (Q1 2025), -$11000.0 (Q2 2024), and $27000.0 (Q1 2024), per Business Quant data.